Stockscreener 앱 받기
11.93
0.08%
-0.010
시간 외 거래:
11.91
-0.02
-0.17%
전일 마감가:
$11.94
열려 있는:
$11.9
하루 거래량:
28.94M
Relative Volume:
3.19
시가총액:
$13.74B
수익:
$14.33B
순이익/손실:
$-3.79B
주가수익비율:
-3.7634
EPS:
-3.17
순현금흐름:
$1.84B
1주 성능:
+2.40%
1개월 성능:
+14.05%
6개월 성능:
+36.03%
1년 성능:
-1.65%
1일 변동 폭
$11.77
$12.13
1주일 범위
$11.42
$12.13
52주 변동 폭
$6.85
$12.68
비아트리스 Stock (VTRS) Company Profile
명칭
Viatris Inc
전화
(724) 514-1465
주소
1000 MYLAN BOULEVARD, CANONSBURG
VTRS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VTRS
Viatris Inc
|
11.93 | 13.75B | 14.33B | -3.79B | 1.84B | -3.17 |
|
ZTS
Zoetis Inc
|
122.24 | 54.10B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.90 | 46.85B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.90 | 43.82B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
30.35 | 34.79B | 16.88B | 666.71M | 251.19M | 0.6132 |
|
UTHR
United Therapeutics Corp
|
517.13 | 21.83B | 3.08B | 1.24B | 1.07B | 25.61 |
비아트리스 Stock (VTRS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-09 | 개시 | Barclays | Overweight |
| 2025-10-15 | 개시 | Truist | Buy |
| 2025-06-06 | 개시 | Goldman | Neutral |
| 2024-07-19 | 재개 | Jefferies | Buy |
| 2023-10-23 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2023-06-23 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2023-04-24 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2023-02-17 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2023-01-27 | 업그레이드 | Jefferies | Hold → Buy |
| 2022-11-10 | 업그레이드 | UBS | Sell → Neutral |
| 2022-11-08 | 업그레이드 | Piper Sandler | Underweight → Neutral |
| 2022-10-21 | 재개 | Jefferies | Hold |
| 2022-06-14 | 개시 | UBS | Sell |
| 2022-05-10 | 다운그레이드 | Piper Sandler | Neutral → Underweight |
| 2022-03-01 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-03-01 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2021-06-15 | 개시 | Citigroup | Neutral |
| 2021-04-07 | 재개 | RBC Capital Mkts | Outperform |
| 2021-03-08 | 다운그레이드 | Goldman | Buy → Neutral |
| 2021-03-02 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2021-02-26 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2021-01-05 | 개시 | Argus | Hold |
| 2020-12-14 | 개시 | Bernstein | Mkt Perform |
모두보기
비아트리스 주식(VTRS)의 최신 뉴스
Opus Genetics Partner Files Supplemental NDA for Presbyopia Drug - TipRanks
Viatris Gets FDA Nod for Generic Sandostatin, Shares Regulatory Updates - Yahoo News Malaysia
Is Viatris Inc. stock safe for conservative investorsEarnings Miss & Fast Moving Stock Watchlists - DonanımHaber
Viatris’ MR-146 gains IND clearance for neurotrophic keratopathy - BioWorld MedTech
Will Viatris Inc. stock outperform Nasdaq index2025 Valuation Update & Verified Technical Trade Signals - DonanımHaber
Update Recap: How Viatris Inc. stock valuations compare to rivalsWeekly Market Report & Fast Entry Momentum Alerts - Улправда
Chemotherapy Induced Anemia Market Intelligence Report 2025-2032, Featuring Amgen, Johnson & Johnson - PharmiWeb.com
Viatris racks up regulatory wins across therapy areas - The Pharma Letter
Viatris Says FDA Approves Octreotide Acetate, Clears MR-146 for Clinical Trials - marketscreener.com
Viatris secures four regulatory milestones across global pipeline - Investing.com
Viatris provides pipeline update on four regulatory milestones - marketscreener.com
Viatris Provides Pipeline Update On Four Regulatory Milestones - TradingView — Track All Markets
New gene therapy and weekly birth control patch move forward at Viatris - Stock Titan
Is Viatris stock outperforming the Dow? - MSN
Viatris Inc. stock rises Wednesday, outperforms market - MarketWatch
Viatris to Present at the 44th Annual J.P. Morgan Healthcare Conference - 富途牛牛
Viatris Inc. stock falls Tuesday, underperforms market - MarketWatch
Does Viatris’ Reshaping Strategy Make Sense After Recent Share Price Swings? - Yahoo Finance
Viatris Recognized as 2025 Best Workplaces™ in Ontario and for Giving Back - The Globe and Mail
Insomnia Drugs Market Outlook 2026-2034: Trends, Shares, and Growth Analysis Featuring Merck & Co., - PharmiWeb.com
Is Viatris Stock Outperforming the Dow? - Barchart.com
Non-operating income (total) of Viatris, Inc. – SIX:VTRS.USD - TradingView — Track All Markets
Risk Analysis: How Viatris Inc VIA stock behaves in tightening cyclesJuly 2025 Snapshot & Verified Swing Trading Watchlist - moha.gov.vn
Discipline and Rules-Based Execution in VTRS Response - news.stocktradersdaily.com
Viatris Inc (VTRS)'s Uncertain Future: Understanding the Barriers to Outperformance - GuruFocus
How Viatris Inc stock reacts to global recession fearsJuly 2025 Spike Watch & Consistent Return Investment Signals - moha.gov.vn
Viatris to Sell Entire Equity Stake in Biocon Biologics for $815 Million - Voice Of HealthCare
Barclays Initiates Coverage of Viatris (VTRS) with Overweight Recommendation - Nasdaq
Barclays Initiates Viatris at Overweight With $15 Price Target - marketscreener.com
Viatris to sell equity stake in Biocon Biologics to Biocon for $815M - MSN
Generic Drugs Market to Reach US$ 942.69 Billion by 2033 at 7.1% - openPR.com
CAM, Khaitan act on Biocon Limited acquiring stake in Biocon Biologics from Serum, Viatris - Bar and Bench
Viatris signs agreements with Biocon on $815m stake sale - MSN
Viatris Inc. Stock Rises Friday, Outperforms Market - 富途牛牛
Viatris Sells Biocon Biologics Stake for $815 Million - TipRanks
Viatris Inc Announces Agreement to Monetize Biocon Biologics Stake - TradingView — Track All Markets
Viatris sells Biocon Biologics stake for $815 million in cash and equity deal - MSN
Viatris to Sell its Equity Stake in Biocon Biologics for $815 Million - marketscreener.com
Viatris sells Biocon Biologics stake for $815 million in cash and equity deal (VTRS:NASDAQ) - Seeking Alpha
Viatris To Sell Equity Stake In Biocon Biologics To Biocon For $815 Mln - Nasdaq
Oculis (Nasdaq: OCS) accelerates Privosegtor into registrational optic neuropathy trials - Stock Titan
Biocon To Absorb Biocon Biologics, Pursue Rs 4,500 Cr QIP To Fund Viatris Payout - BW Businessworld
Biocon to absorb biologics unit, eyes Rs 4,500 cr fund raise to buy Viatris’s residual stake - Moneycontrol
Biocon integrates Biocon Biologics; to raise ₹4,500 crore via QIP to fund Viatris payout - BusinessLine
Viatris shareholders elect directors and approve proposals at annual meeting By Investing.com - Investing.com Nigeria
Viatris Holds Annual Shareholder Meeting on December 5 - TipRanks
Viatris shareholders elect directors and approve proposals at annual meeting - Investing.com India
Mark Cuban Takes Aim at FDA Fees - GuruFocus
Why Viatris Inc. (VIA) stock trades below fair valueJuly 2025 Pullbacks & Weekly Top Gainers Alerts - Newser
Mark Cuban calls for end to generic drug application fees to boost domestic manufacturing - Seeking Alpha
Can Viatris Inc. (VIA) stock survive global slowdownWall Street Watch & Free Daily Entry Point Trade Alerts - Newser
비아트리스 (VTRS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.23%
자본화:
|
볼륨(24시간):